Concerns with beta2-agonists in pediatric asthma - a clinical perspective

被引：13

作者：

Kersten, Elin T. G. ^{[1
]}

Koppelman, Gerard H. ^{[1
]}

Thio, Bernard J. ^{[2
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol,GRIAC Res, POB 30-001, NL-9700 RB Groningen, Netherlands

[2] Medisch Spectrum Twente, Dept Pediat, NL-7512 KZ Enschede, Netherlands

来源：

PAEDIATRIC RESPIRATORY REVIEWS | 2017年 / 21卷

关键词：

beta; 2-agonists; Tolerance; Asthma; Genetic polymorphisms; LONG-ACTING BETA(2)-AGONISTS; AGE-RELATED-CHANGES; BETA-AGONISTS; UNITED-STATES; SALMETEROL; FORMOTEROL; CHILDREN; MORTALITY; THERAPY; BETA(2)-ADRENOCEPTOR;

D O I：

10.1016/j.prrv.2016.05.006

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Beta2-adrenoreceptor agonists (beta 2-agonists) are extensively used in the treatment of childhood asthma. However, there have been concerns regarding their adverse effects and safety. In 2005, the FDA commissioned a "Black Box Warning" communicating the potential for an increased risk for serious asthma exacerbations or asthma related deaths, with the regular use of LABAs. In a meta-analysis of controlled clinical trials, the incidence of severe adverse events appeared to be highest in the 4-11 year age group. Several mechanisms have been proposed regarding the risk of regular use of beta 2-agonists, such as masking patients' perception of worsening asthma, desensitization and downregulation of the beta 2-adrenoreceptor, pro-inflammatory effects of beta 2-agonists, pharmacogenetic effects of beta 2-adrenoreceptor polymorphisms and age related differences in pathophysiology of asthma. In this paper, we review beta 2-receptor pharmacology, discuss the concerns regarding treatment with beta 2-agonists in childhood asthma, and provide suggestions for clinical pediatric practice in the light of current literature. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：80 / 85

页数：6

共 50 条

[11] Beta2-agonists: Friend or foe?
Ford, JG
Iqbal, J
Sunmonu, Y
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 23 (04) : 369 - 375
[12] Addition of intravenous aminophylline to inhaled beta2-agonists in adults with acute asthma
Nair, Parameswaran
Milan, Stephen J.
Rowe, Brian H.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
[13] Inhaled beta2-agonists and corticosteroids in the treatment of children with acute asthma attack
Volovitz, B
Nussinovitch, M
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (11): : 891 - 892
[14] β2-agonists for asthma -: The pediatric perspective
Subbarao, Padmaja
Ratjen, Felix
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2006, 31 (2-3) : 209 - 218
[15] Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis
Becker, Lorne A.
Hom, Jeffrey
Villasis-Keever, Miguel
van der Wouden, Johannes C.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
[16] Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma
Tee, A. K. H.
Koh, M. S.
Gibson, P. G.
Lasserson, T. J.
Wilson, A. J.
Irving, L. B.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
[17] Pharmacogenetics of inhaled long-acting beta2-agonists in asthma: A systematic review
Slob, Elise M. A.
Vijverberg, Susanne J. H.
Palmer, Colin N. A.
Zazuli, Zulfan
Farzan, Niloufar
Oliveri, Nadia M. B.
Pijnenburg, Marielle W.
Koppelman, Gerard H.
Maitland-van der Zee, Anke H.
PEDIATRIC ALLERGY AND IMMUNOLOGY, 2018, 29 (07) : 705 - 714
[18] BETA2-AGONISTS - PHARMACOLOGY AND RECENT DEVELOPMENTS
MELTZER, DL
KEMP, JP
JOURNAL OF ASTHMA, 1991, 28 (03) : 179 - 186
[19] Clinical concerns with inhaled β2-agonists -: Adult asthma
Cockcroft, D. W.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2006, 31 (2-3) : 197 - 207
[20] Apparent efficacy of long acting beta2-agonists in asthma depends on the physiological measure used
Bestall, JC
Adams, NP
Jones, PW
THORAX, 1999, 54 : A65 - A65

← 1 2 3 4 5 →